This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now

AbbVie delivered solid Q2 results with revenue up 10.2% y/y to nearly $17B and adjusted EPS up 23% y/y to $3.65, supported by Skyrizi and Rinvoq. Management expects Skyrizi and Rinvoq to combine for $31B in sales this year, with neither losing patent exclusivity until the next decade, and AbbVie is also positioning next-gen growth via its $10.9B acquisition of Apogee Therapeutics. Wall Street’s average price target of $272.14 implies ~12% upside, alongside a steady dividend growth record (54 years of payout increases).

Analysis

ABBV’s setup is better than the market usually assigns to mature pharma: the issue is not top-line growth anymore, it is the durability of free cash flow once a legacy franchise rolls off. If the new immunology stack keeps compounding, the stock can de-risk from a “dividend bond” multiple toward something closer to a quality large-cap healthcare compounder, which matters more for total return than another modest earnings beat.

The Apogee deal is more important as a pipeline maintenance decision than as near-term EPS accretion. Big pharma increasingly outsources early-stage immunology risk, so the second-order winner is whichever platform can become a repeat acquisition target; the loser is the long-tail of single-asset biotech names that depend on scarcity value. For APGE, the market should treat the valuation as event-driven and capped unless deal terms widen materially.

Contrarianly, consensus is probably underestimating how much downside protection AbbVie has if rates stay elevated: a high, visible payout plus buybacks can support the stock even if sector multiples compress. What could break the thesis is not a macro wobble but an immunology-specific miss—slower uptake, safety noise, or guide-downs that show the replacement cycle is less seamless than management implies. That is a months-long, not days-long, risk.

Key Decisions for Investors

• Add ABBV on post-print weakness over the next 1-3 weeks; target 10-15% upside over 6-12 months if the market continues to reward cash-flow durability.
• Pair trade: long ABBV / short XBI for 1-3 months to express quality-vs-beta; thesis fails if biotech funding sentiment or takeover premium broadens sharply.
• Use APGE only as a merger-arb/watch item: buy only if the spread widens materially; otherwise avoid chasing because upside is largely capped by deal terms.
• Set a falsifier alert on any 2025 guide cut or evidence of prescription growth deceleration in the replacement immunology franchise; that would argue for reducing ABBV immediately.